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defining quality standards. The underlying statement in-
cludes information on current evidence for a reduction in 
mortality with lung cancer screening and the potential epi-
demiologic implications of such a program in Switzerland. 
Furthermore, requirements for lung cancer screening cen-
ters are defined, and recommendations for both the CT tech-
nique and the algorithm for lung nodule assessment are pro-
vided. In addition, related issues such as patient manage-
ment, registry, and funding are addressed. Based on the 
current state of the knowledge, the panel concludes that 
lung cancer screening in Switzerland should be undertaken 
exclusively within a national observational study in order to 
provide answers to several critical questions before consider-
ing broad population-based screening for lung cancer.
 © 2014 S. Karger AG, Basel
 Introduction
 Recently published data from the National Lung 
Screening Trial (NLST) showed a 20% reduction in lung 
cancer mortality in subjects who underwent CT screen-
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 Abstract
 The discussion about setting up a program for lung cancer 
screening was launched with the publication of the results of 
the National Lung Screening Trial, which suggested reduced 
mortality in high-risk subjects undergoing CT screening. 
However, important questions about the benefit-harm bal-
ance and the details of a screening program and its cost-ef-
fectiveness remain unanswered. A panel of specialists in 
chest radiology, respiratory medicine, epidemiology, and 
thoracic surgery representing all Swiss university hospitals 
prepared this joint statement following several meetings. 
The panel argues that premature and uncontrolled introduc-
tion of a lung cancer screening program may cause substan-
tial harm that may remain undetected without rigorous qual-
ity control. This position paper focuses on the requirements 
of running such a program with the objective of harmonizing 
efforts across the involved specialties and institutions and 
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ing compared to those randomized to conventional chest 
X-ray  [1] . In Europe, several randomized controlled stud-
ies using low-dose CT (LDCT) as a screening tool for the 
detection of lung cancer have been or are still being per-
formed  [2–7] . The largest among these European ran-
domized LDCT screening trials, i.e. the Dutch-Belgian 
NELSON Trial, started in 2003 and the final results are 
awaited  [5, 6] .
 Several associations and panels released statements 
on whether or not to implement lung cancer screening in 
clinical practice after the publication of the results of the 
NLST  [8–13] . Some of these statements highlighted the 
need for further improvement of CT screening and de-
scribe specific areas which should be addressed in guide-
lines and recommendations  [11, 14–16] . In contrast, oth-
er associations suggested that screening should be im-
mediately implemented  [17, 18] . Despite the positive 
results of the NLST, we think that the following points 
need to be established before large-scale lung cancer 
screening programs with LDCT can be implemented in 
the clinical routine: the definition of the population at 
risk, the variability of radiological standards and adapt-
ed guidelines for use in national screening programs, the 
number and frequency of screening rounds, the addi-
tional value of lung nodule volumetry versus 2-D mea-
surement, the development of appropriate guidelines for 
the clinical workup of ‘indeterminate nodules’ resulting 
from CT screening programs, the quality of life includ-
ing the psychological consequences of taking part in 
such a program, the role of smoking cessation interven-
tion, and questions related to costs and cost-effectiveness 
 [15, 19] . 
 The discussion about lung cancer screening has also 
started in Switzerland  [20] . The SUVA (Schweizerische 
Unfallversicherungsanstalt), an independent, nonprofit 
company under public law, started a screening program 
for patients with a history of asbestos exposure shortly 
after the publication of the results of the NLST although 
there is no evidence from randomized controlled trials 
that lung cancer screening is effective in such a popula-
tion. This program involves private physicians and is run-
ning in many radiology departments without any quality 
control. Other private institutes have also started to ad-
vertise lung cancer screening. In June 2012, a first meet-
ing of several stakeholders representing the Swiss univer-
sity hospitals took place in an attempt to constitute a na-
tional expert panel to address open questions related to 
lung cancer screening programs. The expert panel pre-
pared this statement paper on the topic, mainly focusing 
on practical issues related to lung cancer screening with 
LDCT, with the awareness that smoking cessation is the 
most efficient method to reduce the number of lung can-
cer cases. Other important issues such as alternative 
methods of lung cancer screening and the implications of 
screening for therapeutic decisions or socioeconomic as-
pects are only briefly or not addressed. The panel agreed 
that, at present, lung cancer screening should be per-
formed exclusively in the framework of an observational 
study accompanied by a prospective registry to ensure 
quality control and to generate longitudinal observation-
al data on aspects of screening-related harm ( table 1 ) and 
to assess the feasibility, the quality, and especially the di-
rect and indirect costs and cost-effectiveness of such an 
intervention.
 The purpose of this paper is to provide information on 
how such a study on lung cancer screening with LDCT 
should be implemented in Switzerland. At this point, it 
seems important to harmonize efforts across the involved 
specialties and institutions, to define quality standards, 
and to develop the appropriate study methodology.
 Table 1.  Potential benefits and harms of lung cancer screening
 Benefits  Harms 
 Mortality reduction  Unnecessary diagnostic procedures and procedure-related complications 
(due to the high number of false-positive findings) 
 Improved quality of life 
(in case of early detection) 
 Radiation exposure  
 Smoking cessation  Overdiagnosis  
 Anxiety and impaired quality of life (due to false-positive results) 
 False sense of reassurance and thus continuation of smoking 
 (in case of a normal CT scan) 
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 Epidemiology and Effectiveness of Lung Cancer 
Screening Programs
 Worldwide, lung cancer is the most commonly diag-
nosed cancer (12.7% of all cancers) and, because of its 
high fatality rate, the most common cause of death from 
cancer  [21] . Poor 5-year survival rates (16%) are related 
to advanced disease at diagnosis [30% Union for Interna-
tional Cancer Control (UICC) stage III and 40% stage IV] 
 [22] . In Switzerland, annually 2,500 men (13% of all can-
cers) and 1,700 women (8% of all cancers) are diagnosed 
with lung cancer and 2,000 men (23% of all cancer deaths) 
and 900 women (13% of all cancer deaths) die from lung 
cancer  [23] . While in men the incidence rate declined in 
Switzerland between the 1980s and 2007, the incidence of 
lung cancer in women almost doubled within the same 
time span and is now reaching a plateau. 
 Earlier studies showed that lung cancer screening 
studies with conventional chest X-ray and sputum cytol-
ogy detected more lung cancers, earlier cancer stages, and 
smaller tumors, but there was no reduction in late-stage 
tumors and lung cancer-specific mortality  [16, 24–35] . 
With its introduction approximately one decade ago, 
LDCT enhanced the detection of lung cancer  [36] .
 According to a recent systematic review that analyzed 
the data of 8 randomized controlled trials and 13 cohort 
studies to assess the possible benefits and harms of lung 
cancer screening, lung cancer-specific mortality was only 
reported in 4 trials (Detection and Screening for Early 
Lung Cancer by Novel Imaging Technology and Molecu-
lar Assays (DANTE)  [2] , NLST  [1] , Danish Lung Cancer 
Screening Trial (DLCST)  [4] , and MILD Trial  [7] )  [16] . 
Of these, the NLST randomized 53,439 smokers and ex-
smokers aged 55–74 years to an annual conventional 
chest X-ray or LDCT over 3 years  [1] . After a median 
follow-up duration of 6.5 years, the NLST found a reduc-
tion in lung cancer-related mortality of 20% in the LDCT 
screening group compared to the chest X-ray group. The 
authors calculated that 320 individuals needed to be 
screened by LDCT to prevent 1 lung cancer-related death. 
In contrast, the smaller DLCST  [4] and the DANTE Trial 
 [2] found no significant mortality reduction with 5 an-
nual rounds of LDCT compared to the usual care at a me-
dian follow-up of 34 and 58 months, respectively. Fur-
thermore, no statistically significant positive or negative 
effects on smoking behavior have been observed in any of 
the LDCT lung cancer screening trials to date.
 The radiation exposure of a single LDCT examination 
is about 4- to 5-fold and 9- to 10-fold lower than the val-
ues of conventional chest CT and PET-CT, respectively 
 [37, 38] . However, a screening program with several 
LDCT examinations may substantially increase the cu-
mulative radiation exposure; for example, an estimated 
average of 8 mSv was delivered in the NLST due to 
screening and diagnostic investigations  [1, 16] . Using ex-
posure models, Bach et al.  [16] estimated that radiation 
exposure from the NLST would result in 1 cancer death 
for every 2,500 individuals screened. The authors con-
cluded that in the NLST population the decrease in mor-
tality due to screening outweighed the risk of radiation, 
but in individuals younger than 42 years or in those at a 
lower risk for lung cancer this may not be the case  [16, 
39] . According to the calculation of Bach et al. [16] , the 
cumulative 10-year risk for the diagnosis of lung cancer 
in participants meeting the minimum entry criteria and 
based on the assumption that they had quit smoking at 
the time of study entry was approximately 2% for the 
NLST. Although screening programs may improve the 
quality of life thanks to the reduced lung cancer-related 
morbidity associated with advanced disease, they may 
also generate anxiety and discomfort, thus potentially 
causing harm  [16] . The Dutch-Belgian NELSON Trial 
included 15,822 subjects. Half of them were randomized 
to the LDCT arm. Screening was performed at baseline 
and 1, 3, and 5.5 years later (4 rounds) with a 10-year 
follow-up period  [5, 6] . In a subgroup analysis of 351 par-
ticipants, 87–99% (depending on the specific question-
naire used) of individuals experienced no discomfort 
due to CT, but 46% were distressed awaiting the CT re-
sults  [40] .
 Screening Population
 Definition of the population to be screened is a chal-
lenging task and requires careful balancing of the benefits 
and harms of a screening program. As discussed above, 
the benefit/harm balance depends substantially on the 
absolute risk of these outcomes. Therefore, lung cancer 
screening programs should focus, like other screening 
programs, on the population at increased risk for the dis-
ease to be prevented and exclude people in which the ben-
efit-harm balance is unlikely to be favorable (e.g. a lung 
cancer screening program in people with no smoking his-
tory or less than 10 pack-years where the number needed 
to screen would be too high). For example, the NLST fo-
cused on subjects between 55 and 74 years of age with a 
cigarette smoking history of at least 30 pack-years with-
out evidence of lung cancer (e.g. hemoptysis or unex-
plained weight loss in the preceding year). The Early Lung 
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Cancer Action Project (ELCAP) defined its population 
similarly  [41] . In the NLST population, the number need-
ed to screen to prevent 1 lung cancer death out of 320 
persons undergoing 3 annual CT scans compared to no 
CT scans  [1] needs to be contrasted with the harm in this 
population. The NLST reported overall mortality and 
major complication rates after diagnostic procedures for 
benign nodules in the LDCT group of 4.1 and 4.5 per 
10,000 participants, respectively, compared to 1.1 and 1.5 
per 10,000 in the chest X-ray group  [1, 16] . Additionally, 
screening may identify lung cancer that would not have 
affected the patient’s life if left untreated, a phenomenon 
termed overdiagnosis  [42] . Bach et al.  [43] addressed the 
problem of overdiagnosis in 2007 using calculations 
based on CT screening. They showed that, despite the fact 
that more tumors were detected by CT screening, the 
numbers of advanced tumors and tumor related deaths 
were not reduced. Other studies based on X-rays as well 
as one recent study on LDCT have reported an overdiag-
nosis rate of about 25%  [16, 44–46] . The findings of the 
NLST suggested that overdiagnosis might have occurred, 
but due to the study design this cannot be ascertained and 
quantified at this stage.
 Evidence of both the benefits and the harms of early 
lung cancer detection programs is still scarce and there-
fore it is currently difficult to define a population other 
than the one defined by the NLST in which the benefit-
harm balance of lung cancer screening is likely to be fa-
vorable. A recent study by Kovalchik et al.  [47] analyzed 
the NLST population concerning their risk of developing 
lung cancer and showed that in subjects with multiple risk 
factors the benefit clearly outweighs the harm. The find-
ings of this analysis possibly call for individual risk strat-
ification in lung cancer screening programs, which is like-
ly to improve the cost-effectiveness of LDCT screening 
 [47] . Also, the most appropriate number of screening 
rounds is uncertain at this stage. Therefore, we suggest 
that, if screening is performed, the screened population 
should be the same as in the NLST, focusing on individu-
als aged 55–74 years with at least 30 pack-years of smok-
ing history, either active or discontinued for less than 
15 years, with no clinical symptoms of lung cancer. The 
recommendation of extending the screened population 
to other age groups, to patients with COPD, to those with 
a previous history of lung cancer, or to those with a lower 
level of smoking exposure  [17] is not supported by the 
current evidence, it is likely to be harmful, and it should 
therefore be avoided. Recent studies suggest that the se-
lection criteria for lung cancer screening can be refined 
 [48] .
 Minimal Requirements of a Lung Cancer Screening 
Center
 Performed within a national prospective trial or regis-
try, we propose that lung cancer screening should only be 
done at institutions with the necessary infrastructure and 
expertise for the multidisciplinary workup of lung nodules 
and management of lung cancer, which are most likely to 
replicate the results of the NLST  [14, 15, 49, 50] . These re-
quirements should be enforced by the health authorities 
similar to the screening program for breast cancer and 
should adhere to standards for training, infrastructure, 
procedures, and documentation including the following:
 • A chest imaging unit with low-dose HRCT (for the 
minimum technical requirements, see Technique and 
Algorithm of Lung Nodule Assessment), percutane-
ous CT-guided needle biopsy, and PET-CT
 • A respiratory medicine unit with state-of-the-art car-
diopulmonary exercise testing facilities and video 
bronchoscopy
 • A cytopathology department
 • A thoracic surgery unit experienced in minimally in-
vasive surgical techniques
 • Comprehensive pre- and postoperative care, including 
an intensive care unit and pulmonary rehabilitation
 • An oncology unit with organ-specific multidisci-
plinary tumor boards on a routine basis
 • A smoking cessation program and counseling
 All specialists involved should be board certified in 
their respective disciplines.
 Patient information on lung cancer screening should 
be provided both orally and in written form with the help 
of specific information material. The patients are assessed 
according to the NLST criteria, which does not provide 
an explicit risk prediction for lung cancer but restricts the 
screening to a population at increased risk for lung cancer 
compared to subjects who, for example, smoked less or 
are outside of the age range used in the NLST  [47, 50, 51] . 
The information material should provide key data about 
the expected screening benefits and harms in a neutral 
and nonpersuasive way  [14] , including an explanation of 
the difference between a screening test and a diagnostic 
procedure, the facts that screening will not detect all can-
cers, that screening is more likely to detect a benign ab-
normality than cancer, and that the benefit-harm ratio is 
still unclear, and the potential risks of invasive diagnostic 
and therapeutic procedures  [13, 15] . A flowchart may be 
provided showing the possible scenarios  [49] . Sufficient 
time should be allowed for decision making and the first 
screening CT should not be performed on the same day 
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the information is provided. Smoking cessation programs 
are to be systematically integrated. After a negative 
screening round, patients should be informed of the 
symptoms of lung cancer  [15] .
 Institutions performing lung cancer screening should 
adopt an ethical chart stating that they do not recruit pa-
tients through direct or indirect advertisement, use fear 
of cancer to promote lung cancer screening, let patients 
believe that the cancer risk can be eliminated by screen-
ing, or offer screening at reduced costs with the aim of 
generating profit from additional diagnostic and thera-
peutic procedures  [50] .
 Technique and Algorithm of Lung Nodule 
Assessment
 Imaging Protocol
 For lung cancer screening, at best a 64-slice multide-
tector CT scanner or a later generation scanner should be 
used. This is to achieve the optimal spatial resolution for 
accurate and reproducible measurements of small nod-
ules. The slice thickness should be 1.5 mm or less and 
imaging has to be performed without contrast in full in-
spiration. A low-dose protocol must be used with an ef-
fective dose of around 1 mSv depending on the patient’s 
weight and including iterative reconstruction whenever 
possible.
 Lung Nodule Assessment
 A lung nodule is defined as a small, approximately 
spherical, nonlinear, circumscribed focus of abnormal 
soft tissue  [52, 53] . Lung nodules can be categorized as 
calcified nodules in the presence of a benign pattern of 
calcium, assolid nodules if they have areas of homoge-
neous soft tissue attenuation, as partly solid nodules if 
they have both solid and ground-glass attenuation, and as 
nonsolid (pure ground-glass) nodules if they only have 
ground-glass attenuation. Although the shape of a solid 
lung nodule may add to the evaluation regarding its po-
tential malignancy, the size or volume of the nodule 
should preferably be used as the objective criteria  [54–
56] .
 The expert panel proposes employment of the algo-
rithm outlined in the statement of the National Compre-
hensive Cancer Network (NCCN) for the management of 
solid nodules and partly/nonsolid nodules  [9] . In case of 
new nodules detected at the annual or follow-up LDCT, 
the algorithm for the management of solid nodules and 
partly/nonsolid nodules should be applied in cases of no 
suspected infection. The workup for solid nodules should 
be in accordance with the Fleischner Society criteria  [57] . 
There are new recommendations from the Fleischner So-
ciety regarding the management of subsolid nodules, 
which still need to be integrated into the current algo-
rithm  [58] . For nonsolid nodules, the guidelines follow 
the recommendation of Godoy and Naidich  [59] . Al-
though in all running screening programs size is the most 
important factor, results from the NELSON Trial, for ex-
ample, show that perifissural nodules are mostly benign 
and do not need further workup even if they are growing 
 [54, 60] . In cases of suspected infection, a follow-up 
LDCT should be considered after 6–8 weeks and if the 
nodules increase in size a diagnostic workup is necessary.
 Though all of these algorithms utilize the mean nodule 
diameter as the only relevant criterion, the largest 
 European lung cancer screening trial, i.e. the NELSON 
Trial, focused on the volume and the change in volume as 
the major criteria for lung nodule assessment and further 
management  [6] . French experts of the French inter-
group (IFCT) and the Groupe d’Oncologie De Langue 
Française (GOLF) also adopted such an approach  [10] . 
The volumetric analysis may allow a more accurate and 
more differentiated assessment of lung nodules. The pre-
liminary results of the NELSON Trial suggest that volu-
metry of the nodule may be a useful parameter to reduce 
the false-positive and false-negative rates, but this tech-
nology is not widely available yet  [6] . Nevertheless, the 
panel advocates the use of lung nodule volumetry in the 
case of a standardized CT protocol and use of the same 
software for each measurement.
 Computer-assisted detection (CAD) of lung nodules 
has recently become more important. Several studies 
have shown that the use of CAD in radiological practice 
can significantly improve the diagnostic accuracy of pul-
monary nodule detection  [61, 62] . In an analysis based on 
data from the NELSON Trial, the sensitivity of CAD to 
detect lung nodules was 96.7% compared to 78.1% for 
conventional double reading without CAD  [61] . This dif-
ference seems to be particularly explained by the observa-
tion that nodules attached to vessels are often missed by 
conventional reading. Therefore, the panel advocates the 
use of a CAD system as a second (or additional) reader in 
a lung cancer screening program. No benefit has been 
shown for double reading  [63] .
 Workup of Solid Nodules. If malignancy is highly prob-
able, then the nodule should be surgically removed. PET-
CT as a single method has a negative predictive value of 
only 81% as shown by van’t Westeinde et al.  [64] , which is 
insufficient to rule out malignancy. However, the findings 
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of other studies suggest that PET-CT can be used to re-
duce the number of false-positive findings, especially 
when used in combination with other diagnostic proce-
dures  [65, 66] . Accordingly, Ashraf et al.  [66] found that 
the use of both PET and the volume doubling time in-
creases the sensitivity and specificity for lung cancer di-
agnosis to 90 and 82%, respectively.
 Workup of Subsolid Nodules. The management of sub-
solid nodules should be based on the recommendations 
of the Fleischner Society  [58] . As shown in the MILD Tri-
al, the growth rate of subsolid nodules is usually very low, 
and thus active prolonged surveillance is recommended 
 [67] . This may be adapted according to the type of sub-
solid nodule, the initial nodule size, and the past history 
of lung cancer  [68] . In fast growing ground-glass lesions, 
PET has rarely been proven to predict malignancy, and 
thus surgery is often the diagnostic strategy of choice  [55, 
59, 69] .
 Besides lung cancer-related mortality, the NLST also 
found a 6.7% decrease in all-cause mortality  [1] . There are 
several pathologies that may be found when an LDCT is 
being performed and this may affect mortality. Graham 
et al.  [70] , for example, showed that a diagnosis of severe 
coronary calcification has a significant impact on mortal-
ity. It is therefore possible that analysis of imaging fea-
tures other than lung nodules may have an impact on sur-
vival or other clinical outcomes. The relevance of these 
additional findings has been investigated by several 
groups  [71–73] . In all of these studies the number of sig-
nificant incidental findings did not exceed 7%. This was 
influenced by the wider scan range in that population, 
covering parts of the upper abdomen  [72] . Priola et al. 
 [72] estimated that the additional incurring costs might 
not be extensive. However, currently there is no consen-
sus on whether or not these incidental findings should be 
reported. This has also been discussed based on data of 
the NELSON Trial, and van de Wiel et al.  [71] advised 
against systematic reporting of all incidental findings.
 Patient Management
 Infrastructural Needs and Organization
 The individual management of patients participating 
in a lung cancer screening study is of crucial importance. 
Dedicated, well-trained medical and paramedical staff 
embedded within a well-organized infrastructure is the 
key to running an efficient lung cancer screening pro-
gram. The required infrastructure for such a center as 
well as how participants should be informed is discussed 
in more detail in Minimal Requirements of a Lung Can-
cer Screening Center. 
 The core facility for patient management should be a 
dedicated outpatient clinic within a chest unit to guaran-
tee high-quality patient counseling and treatment. In ad-
dition, the patient flow and the interaction between the 
several involved medical specialties and the referring GP 
are key issues that need to be precisely defined in written 
protocols.  Figure 1 summarizes a possible workflow for 
the management of patients.
 Interaction between Radiologists, Pulmonologists, and 
Other Specialists
 Interaction between specialists becomes important if a 
CT scan is abnormal. In weekly interdisciplinary meet-
ings (radiology, pulmonary medicine, and thoracic sur-
gery) any pathological CT finding requiring further in-
vestigation should be discussed. Lung nodules for which 
a CT follow-up is planned within the screening process 
do not necessarily need interdisciplinary assessment. 
 The joint decision of the interdisciplinary assessment 
team on the necessary further diagnostic or therapeutic 
steps should be documented in writing and constitute the 
basis upon which the chest unit discusses the findings of 
the CT scan with the patient.
 Communication of Pathological Findings to the 
Patient, Coordination of Further Diagnostic Steps, 
and Communication with the Referring Physician
 The chest unit should discuss all pathological findings 
described by the radiologist (this also includes extratho-
racic findings) with the patient during a medical appoint-
ment. A letter detailing the results of the CT scan and 
recommendations regarding further investigations and/
or follow-up CT screening should be forwarded to the 
referring physician, the patient, and members of the in-
terdisciplinary assessment team. The chest unit may or-
ganize further investigations. It is important that the 
chest unit play an active role in the management of the 
patient in accordance with the referring physician.
 Smoking Cessation
 All participating patients should be advised to cease 
smoking and they should be actively encouraged to par-
ticipate in a structured smoking cessation program. 
Counseling and referral should be repetitiously offered to 
the participant whenever she/he is seen in the chest unit. 
Smoking cessation programs should follow international 
recommendations, for instance those of the Centers for 
Disease Control and Prevention  [74] . 
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 Costs and Cost-Effectiveness
 In the NLST, 320 patients needed to be screened to 
avoid 1 cancer death. McMahon et al.  [75] assessed the 
cost-effectiveness of the NLST comparing the estimated 
quality-adjusted life years (QALY; measurement of the 
disease burden, including the quality and quantity of life 
lived) for lung cancers based on the screening test to ei-
ther no intervention or the addition of a smoking cessa-
tion program for both study arms  [75] . In the latter pub-
lication, the calculated costs ranged between USD 126,000 
and USD 169,000 per QALY for current and former 
smokers aged 50–74 years with a smoking history of at 
least 20 pack-years. If only subjects with at least 40 pack-
years were included in the analysis, the costs were re-
duced to a range between USD 110,000 and USD 166,000 
per QALY. If linked to a smoking cessation program with 
an assumed background cessation rate of 6%, the costs 
were estimated to be USD 75,000 per QALY for subjects 
aged ≥50 years and at least a 20-pack-year smoking his-
The patient is referred for CT screening to the chest unit by the GP (web-based form which
includes the criteria for screening eligibility).
The institute of radiology performs the CT scan. The patient is dismissed home without
discussing the results of the CT scan (exception: any disease requiring immediate action).
The chest unit sees the patient, gives advice to the patient regarding smoking cessation,
explains the potential harms and benefits of the CT, and obtains informed consent.
The chest unit books a CT appointment and forwards the electronic file to the database.
The institute of radiology interprets the CT scan and reports the results using a
structured electronic form. The institute of radiology makes a decision regarding the
follow-up sequence and forwards the electronic report to the database.
The chest unit explains the CT findings to the patient. The chest unit sends a letter with the 
results and recommendations (including the next CT appointment) to the GP, the patient, 
and the members of the interdisciplinary assessment team. The chest unit organizes further 
investigations if needed.
The chest unit sends a letter with the appointment date to the patient.
The chest unit forwards the electronic form with the decision and recommendations to 
the database.
Abnormal CT scan:
Any pathological CT finding within the thorax
requiring potential further investigation will be
discussed in an interdisciplinary meeting
(exception: lung nodules for which a CT follow-up
is planned within the screening program).
The institute of radiology sends the report to the
chest unit.
Normal CT scan:
The institute of radiology
sends a letter with the results
and the date of the next CT
appointment to the chest unit.
 Fig. 1. Summary of a possible workflow for 
the management of patients. 
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tory. A comparison of these data with the cost of colorec-
tal screening (USD 13,000–32,000 per QALY) or breast 
cancer screening by mammography (USD 47,700 per 
QALY) implies that the population to be included in a 
lung cancer screening program needs to be defined very 
carefully. Another study by Goulart et al. [76] calculated 
that LDCT screening will avoid 8,100 premature deaths 
from lung cancer at a cost of USD 1.3–2 billion in annual 
national health care expenditures in the USA. Thus, the 
additional cost of screening to avoid 1 death would be 
USD 240,000. In summary, to date no study has been able 
to show that LDCT screening is cost-effective. Further 
analysis of the NLST may determine whether lung screen-
ing is cost-effective; however, these estimations largely 
depend on the parameters and assumptions used. For ex-
ample, Pyenson et al.  [77] calculated that the cost per life 
year saved would be below USD 19,000, which is compa-
rable to the cost of mammography screening (USD 
18,000).
 The cost of an LDCT and 2 outpatient appointments 
is approximately CHF 270–350 and CHF 250, respec-
tively, based on the Swiss health tax system (TARMED), 
thus resulting in a direct cost of one screening round of 
approximately CHF 520–600. However, these direct 
costs are only a fraction of the total incurring costs, as 
the diagnostic workup and treatment related-costs can-
not be reliably predicted from the available data. It is 
therefore crucial to gain more knowledge of these costs, 
not only for the health authorities but also for insurance 
providers. 
 Call for a National Registry
 Quality maintenance is the ongoing process of estab-
lishing and improving the standards for all components 
of a program. In a multidisciplinary setting, monitoring 
of quality is critical for the success of a lung cancer screen-
ing program. Comparison of practices and outcomes be-
tween screening centers is needed to guarantee high-
quality standards at a national level. We therefore suggest 
setting up a common national registry with the following 
goals:
 • To characterize the population that undergoes lung 
cancer screening. This should ensure that only eligible 
subjects are included and not those who do not, ac-
cording to the current evidence, qualify for the pro-
gram.
 • To monitor the adherence to quality standards for all 
steps of the program. Quality indicators should be col-
lected for the initial encounter where subjects are in-
formed about the potential harms, for the screening 
CTs, for the invitation and adherence to a smoking 
cessation program, and for the follow-up diagnostic 
and therapeutic procedures that follow the screening 
CTs. 
 • To collect short-, mid-, and long-term data on benefit 
and harm outcomes.
 • To evaluate the costs and cost-effectiveness not only of 
the screening procedure itself but also of all consecu-
tive costs.
 Such a registry is a central element for quality assur-
ance and would provide a basis for detecting deviations 
from standardized procedures and a comparison of out-
comes with those of the NLST and other studies. Also, 
comparisons of quality and outcomes across centers 
and over time need to be performed. These data would 
be required to inform the decision of whether and how 
to  implement a lung cancer screening program in 
 Switzerland, as well as for discussions with legal authori-
ties and health insurances. However, as the proposed 
study design would be a purely observational study with-
out a control group, it will not be possible to assess the 
efficacy of CT screening regarding the reduction of lung 
cancer mortality.
 Conclusion
 Lung cancer is a lethal disease associated with sub-
stantial medical and economic burdens. The NLST is 
currently the only randomized trial that has shown that 
lung cancer screening may reduce mortality, and the re-
sults of the NELSON Trial are eagerly awaited. The pos-
sible advantage of LDCT screening has to be balanced 
against the potential of inducing harm. Despite the ben-
efit of early lung cancer detection and the prevention of 
tumor-related deaths, LDCT screening may produce 
harm, e.g. through unnecessary biopsies, radiation ex-
posure, and psychosocial stress. Before lung cancer 
screening can be broadly implemented in clinical prac-
tice in Switzerland, these critical issues have to be ad-
dressed appropriately. Therefore, based on the current 
evidence it seems important to stress that lung cancer 
screening should be exclusively performed in the set-
ting of an observational study organized by skilled pro-
fessionals, in institutions with the appropriate infra-
structure and expertise, and based on recommendations 
set forth by harmonized guidelines and standardized 
procedures.
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